Compare IDEXX Laboratories, Inc. (IDXX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs WD 40 Company — how do they compare? IDEXX Laboratories, Inc. trades at $558.29 (market cap $44.48B), while WD 40 Company trades at $235.83 (market cap $3.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.8× WD 40 Company's market cap, and WD 40 Company pays a 1.7% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | WDFC | |
|---|---|---|
Market Cap | $44.48B | $3.22B |
Sector | Health | Technology |
52-Week High | $766.68 | $264.91 |
52-Week Low | $520.87 | $187.52 |
Enterprise Value | $45.38B | $3.27B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
WDFC trades at $239.59, down 2.92% today, with a bullish technical signal supported by moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations at $2.33 EPS versus $1.58 expected, driven by strong sales growth. The company maintains solid profitability with a 13.22% net income margin and positive operating cash flow of $87.93 million in 2025, though 2026 projections show slight margin compression.
The outlook is mixed: strong brand moat and consistent cash flow support dividends, but high valuation multiples (P/E 37.5) and analyst caution (71% hold rating) limit near-term upside. Risks include input cost pressures and competitive maintenance markets. Institutional sentiment leans neutral despite recent earnings strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
